MRI Contrast Media Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The mri contrast media market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising demand for early diagnosis, increasing demand for diagnostic accuracy and patient outcomes, increased public awareness, development of combination imaging modalities, identification of novel use cases for contrast agents.

The mri contrast media market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rise in cancer cases, growing prevalence of chronic diseases, increasing research and development investment and activities, increasing healthcare expenditure, expanding applications of MRI. Major trends in the forecast period include advancement with collaborative research, technological advancements, product innovation, development of safer and more effective contrast agents, product innovations by pharmaceutical and biotechnology companies.

The anticipated increase in cancer cases is expected to drive growth within the MRI contrast media market. This rise in cancer cases is attributed to a multitude of factors, including demographic shifts, lifestyle choices, environmental influences, genetic predispositions, and advancements in healthcare practices. MRI scans utilize contrast agents containing gadolinium-based compounds to enhance visualization by modifying tissue magnetic properties, aiding in the detection, sizing, and characterization of tumors, as well as evaluating their invasion into surrounding tissues. For instance, a report published by the World Health Organization (WHO) in February 2024 revealed that the global estimated number of new cancer cases surged to 20 million in 2022, resulting in 9.7 million deaths. Projections indicate a substantial increase in cancer cases by 2050, with an anticipated 77% rise to over 35 million new cases, compared to the estimated 20 million cases in 2022. Hence, the mounting incidence of cancer serves as a driving force behind the expansion of the MRI contrast media market.

Key players in the MRI contrast media market are strategically focused on developing and distributing advanced products, such as macrocyclic gadolinium-based contrast agents (GBCA), to augment the diagnostic capabilities and safety profile of MRI imaging procedures. Macrocyclic gadolinium-based contrast agents (GBCA) represent a category of contrast agents utilized in medical imaging, particularly in magnetic resonance imaging (MRI). For instance, in February 2023, Guerbet, a France-based provider of MRI contrast media, unveiled the Elucirem (gadopiclenol) injection. Distinguished by its highly stable macrocyclic gadolinium-based contrast agent (GBCA), Elucirem (gadopiclenol) injection boasts the highest relaxivity in its class for MRI. This innovative formulation of gadopiclenol demonstrates exceptional efficacy in detecting and visualizing lesions with abnormal vascularity across various regions of the central nervous system and the body.

In March 2023, Bracco Imaging S.p.A., an Italy-based healthcare company, concluded the acquisition of the remaining 49% stake in Bracco-Eisai Co. Ltd. for an undisclosed sum. This strategic move is aimed at facilitating swift and adaptable responses to the evolving healthcare industry landscape, with a focus on achieving sustainable contributions to patient care through product utilization. Bracco-Eisai Co. Ltd., based in Japan, is recognized for its provision of MRI contrast media, contributing to Bracco Imaging S.p.A.'s comprehensive portfolio of healthcare solutions.

Major companies operating in the MRI contrast media market are Bayer AG, GE Healthcare Technologies Inc., Fresenius Kabi AG, Fujifilm Holdings Corporation, JB Chemicals and Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd., Bracco S.p.A., Miltenyi Biotec B.V. & Co. KG, Lantheus Medical Imaging Inc., Guerbet LLC, Curium Pharma, Spago Nanomedical AB, AMAG Pharmaceuticals Inc., Nanopet Pharma GmbH, Trivitron Healthcare, Beijing Beilu Pharmaceuticals Company Limited, Unijules Life Sciences Ltd., Taejoon Pharm Co. Ltd., Mediso USA LLC, Nano Therapeutics Pvt. Ltd., Livealth Biopharma Pvt Ltd., BioPAL Inc., Vitalquan LLC, Shubhra Biotech Pvt Ltd., Rege Imaging & Cine Films Private Limited, Polarean Inc.

North America was the largest region in the MRI contrast media market in 2024. The regions covered in the mri contrast media market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mri contrast media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The MRI contrast media market consists of sales of gadopentetate dimeglumine (Gd-DTPA), gadodiamide, diatrizoate, and gadoversetamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

MRI contrast media refers to substances utilized in magnetic resonance imaging (MRI) to heighten the visibility of internal body structures. These contrast agents function by modifying the magnetic properties of tissues, thereby enhancing the contrast in resultant images.

The primary MRI contrast media products include extracellular contrast agents, blood-pool agents, and hepatobiliary agents. Extracellular contrast agents are employed in MRI to augment the visibility of internal body structures. They find application in diagnosing various conditions such as neurological disorders, musculoskeletal disorders, cardiovascular disorders, cancer detection, and more. These products are utilized by a range of end-users including hospitals, diagnostic and imaging centers, research institutes, and others.

The MRI contrast media market research report is one of a series of new reports that provides MRI contrast media market statistics, including MRI contrast media industry global market size, regional shares, competitors with an MRI contrast media market share, detailed MRI contrast media market segments, market trends, and opportunities, and any further data you may need to thrive in the MRI contrast media industry. This MRI contrast media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.